doi: 10.1161/hy09t1.092927
(Hypertension. 2001;38:543.)
© 2001 American Heart Association, Inc.
Genetics and Gene Therapy |
Gene Therapy for Hypertension
The Preclinical Data
Department of Physiology, College of Medicine, University of Florida, Gainesville.
M. Ian Phillips, PhD, DSc, Department of Physiology, College of Medicine, Box 100274, University of Florida, Gainesville, FL 32610-0274. E-Mail MIP{at}phys.med.ufl.edu
Abstract
Abstract—— Despite several drugs for the treatment of hypertension, there are many patients with poorly controlled high blood pressure. This is partly because all of the available drugs are short-lasting (
24 hours), have side effects, and are not highly specific. Gene therapy offers a possibility of producing longer-lasting effects with precise specificity based on the genetic design. Preclinical studies on gene therapy for hypertension have taken 2 approaches. Chao et al have performed extensive studies on gene transfer to increase vasodilator proteins. They have transferred kallikrein, atrial natriuretic peptide, adrenomedullin, and endothelin NO synthase into different rat models. Their results show that blood pressure can be lowered for 3 to 12 weeks with the expression of these genes. The antisense approach, which we began by targeting angiotensinogen and the angiotensin type 1 (AT1) receptor, has now been tested independently by several different groups in multiple models of hypertension. Other genes targeted include the ß1-adrenoceptor, thyrotropin-releasing hormone, angiotensin gene-activating elements, carboxypeptidase Y, c-fos, and CYP4A1. There have been 2 methods of delivering antisense: one is by oligodeoxynucleotides, and the other is with full-length DNA in viral vectors. All the studies show a decrease in blood pressure lasting several days to weeks or months. Oligos are safe and nontoxic and could be delivered orally or eventually by skin patches. Systemic delivery of recombinant adeno-associated virus with DNA antisense to AT1 receptors in adult rodents decreases hypertension for up to 6 months. We conclude that there is sufficient preclinical data to give serious consideration to phase I trials for testing some of the antisense oligodeoxynucleotides, although testing the viral vectors needs much more work.
Key Words: genes • drug therapy • kallkirein • renin angiotensin system • adrenergic receptor blockers • oligonucleotides • antisense • adeno-associated virus
This article has been cited by other articles:
 |
|
 |
|
  Y. Wang and Z. Sun Klotho Gene Delivery Prevents the Progression of Spontaneous Hypertension and Renal Damage Hypertension, October 1, 2009; 54(4): 810 - 817. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Sun, M. Bello-Roufai, and X. Wang RNAi inhibition of mineralocorticoid receptors prevents the development of cold-induced hypertension Am J Physiol Heart Circ Physiol, April 1, 2008; 294(4): H1880 - H1887. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Brain and A. D. Grant Vascular Actions of Calcitonin Gene-Related Peptide and Adrenomedullin Physiol Rev, July 1, 2004; 84(3): 903 - 934. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Chu, S. Iida, D. D. Lund, R. M. Weiss, G. F. DiBona, Y. Watanabe, F. M. Faraci, and D. D. Heistad Gene Transfer of Extracellular Superoxide Dismutase Reduces Arterial Pressure in Spontaneously Hypertensive Rats: Role of Heparin-Binding Domain Circ. Res., March 7, 2003; 92(4): 461 - 468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Y.H. Chan, L.-L. Wang, H.-Y. Lee, and S. H.H. Chan Augmented Upregulation by c-fos of Angiotensin Subtype 1 Receptor in Nucleus Tractus Solitarii of Spontaneously Hypertensive Rats Hypertension, September 1, 2002; 40(3): 335 - 341. [Abstract] [Full Text] [PDF]
|
|